预约演示
更新于：2025-04-17
Flurbiprofen
氟比洛芬
更新于：2025-04-17
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C15H13FO2 |
InChIKeySYTBZMRGLBWNTM-UHFFFAOYSA-N |
CAS号5104-49-4 |
关联
131
项与 氟比洛芬 相关的临床试验CTR20250642
氟比洛芬凝胶贴膏在中国健康受试者外用条件下单次给药的人体生物等效性临床试验
CTR20250422
氟比洛芬凝胶贴膏（40mg）在中国健康受试者空腹外用条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验
NCT06823284
Characterization of Relative Bioavailability of a Newly Developed Esflurbiprofen Topical System (EFTS) in Comparison with a Marketed Oral Flurbiprofen-containing Tablet Formulation After Multiple-dose Administration Including EFTS Adhesion Assessment - a Phase I, Open-label, Randomized, 2-period, Cross-over Study in Healthy Subjects
100 项与 氟比洛芬 相关的临床结果
登录后查看更多信息
100 项与 氟比洛芬 相关的转化医学
登录后查看更多信息
100 项与 氟比洛芬 相关的专利（医药）
登录后查看更多信息
5,363
项与 氟比洛芬 相关的文献（医药）2025-06-01BIOMATERIALS
Inhibition of PDT-induced PGE2 surge for enhanced photo-immunotherapy
Article
作者: Lu, Yichao ; Mao, Jiapeng ; Liu, Xu ; Huang, Jiaxin ; Yang, Fuchun ; Zhou, Huanli ; Li, Xiang ; Guo, Xuemeng ; Luo, Lihua ; You, Jian ; Du, Yongzhong ; Wang, Sijie
Nowadays, photodynamic therapy (PDT) offers a non-invasive tumor treatment with high safety profiles and minimal side effects, implying a promising clinical application for patients with malignant tumors. However, the lack of efficacy in metastasis and recurrence still notably limits its application. To solve this problem, one promising strategy is to improve the immune response activated by PDT. Unfortunately, tumor cells derived PGE2 could create immunosuppressive microenvironments and impair the function of multiple immune cells, leading to a failure of immune system activation. Moreover, our research revealed the up-regulation of Ptgs2 in tumor cells after the PDT process, which is associated with a series of pro-tumor effects, including proliferation, invasion, metastasis, apoptotic resistance, and immune evasion. Consequently, controlling the PGE2 surge induced by PDT is crucial for optimizing the efficacy of photo-immunotherapy. Therefore, we combined the regulation of the COX2-PGE2 axis with PDT. The addition of COX inhibitors (COX-Is) could improve the efficiency of PDT, reduce the immunosuppressive effect of PGE2, and help dying tumor cells activate the immune system. Herein, a tumor-targeted nano-delivery platform (FI@T-Lipo) was developed using advanced microfluidic technology. FI@T-Lipo based PDT showed a systemic therapeutic effect in triple negative breast cancer through reclaiming the anti-tumor effect of the immune system under COX2-PGE2 blockage. In a word, we developed an in-situ tumor vaccination strategy based on COX-Is enhanced PDT, which could alleviate intra-tumoral immune suppression and boost immune system activation. Our study offers a promising modality for advancing clinical treatment strategies for metastatic malignant tumors.
2025-06-01WATER RESEARCH
CO2 geological sequestration can remove emerging contaminants in groundwater: The important role of secondary mineral carbonates
Article
作者: Hu, Bingbing ; Cui, Zhongjie ; Zhang, Xuejie ; Huang, Li-Zhi ; Zhu, Liandong
Carbon dioxide (CO2) injection has been proposed as a strategy for carbon sequestration, while uncertainties persist regarding its effects on groundwater. Concerns have been raised that CO2 mineralization and sequestration could potentially lead to groundwater contamination. However, our study demonstrates its capability to mitigate pollution. The injection of CO2 facilitates the rapid dissolution of minerals, releasing Ca(II), Mg(II), and Fe(II) and forming secondary carbonate minerals, such as CaCO3, MgCO3, and FeCO3. The in-situ generated FeCO3 can activate oxygen to produce hydroxyl radicals (•OH) under oxic condition, thereby enhancing the degradation of emerging organic contaminants in groundwater, such as 2,4,6-tribromophenol, flurbiprofen, diclofenac, carbamazepine, phenol, and sulfamethoxazole. Mechanism studies suggest that this process is enhanced by the conversion of in-situ formed FeCO3 into a two-dimensional goethite nanosheet structure, which provides a larger specific surface area and enables more Fe(II) to be adsorbed on the mineral surface. The formation of Fe-O coordination bonds effectively reduces the loss of •OH at the interfacial reaction layer. The study further distinguishes and quantifies the contributions of different Fe(II) forms to •OH generation. The transformation pathways of the six contaminants and the toxicity of their intermediates are also analyzed. CaCO3 and MgCO3 do not exhibit the ability to degrade pollutants, but play a role in carbon mineralization. This work reveals that secondary minerals generated through the CO2 mineralization and sequestration process display simultaneous capabilities of contaminant degradation and carbon fixation. Such activities are pivotal not only for the environmental fate and transformation of emerging contaminants in groundwater but also for regulating the carbon cycle.
2025-05-01EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
Studying the effects of polymers on therapeutic deep eutectic solvents’ formation and stability: A thermal analysis-based approach to optimise polymer selection
Article
作者: Andrews, Gavin P ; Li, Shu ; Jones, David S ; Abdelquader, Magdy M
Therapeutic deep eutectic solvents (THEDES) are the liquids produced upon mixing two solid materials, where at least one of them is an active pharmaceutical ingredient. The strong hydrogen bonding (HB) between the parent materials is the reason for such profound depression in their melting points. THEDES formation can improve drugs' solubility and permeation characteristics. However, this can be limited by their encapsulation within drug delivery platforms e.g., polymeric matrices which might disrupt the HB network of THEDES by introducing new HB active sites into the mixture. Despite this, the effects of polymers on THEDES stability are not well-documented. In addition, the polymers' impact on THEDES formation during end-to-end production has not been studied. In this work, these issues were addressed by employing thermal processing of polymers and drugs. The dually active lidocaine: flurbiprofen (1:1) THEDES was utilized in addition to model polymers, namely polyethylene-co-vinyl acetate (PEVA), polyethylene oxide (PEO) and Eudragit® RL PO (EuRLPO). Firstly, probing the interaction between the polymers and the individual components of THEDES revealed that PEVA has no affinity towards both drugs while PEO can interact with flurbiprofen, and EuRLPO can interact with lidocaine. Then, to study the effect of the polymers on THEDES formation and stability, a valid in-situ method was developed to quantify THEDES in its mixture using modulated temperature differential scanning calorimetry (MTDSC). MTDSC data showed that the three polymers retarded THEDES formation in the following order PEVA < EuRLPO < PEO. This retardation was attributed to increased medium viscosity and the subsequent reduction in THEDES formation rate. Increasing the heating time led to complete THEDES formation in the case of PEVA and EuRLPO but not with PEO. This result was explained based on the polymers' interaction with THEDES parent drugs and inputs from polymers' viscoelastic properties. On the other hand, introducing the polymer after THEDES formation mitigated their viscosity effect but their interaction with the parent drugs remained an issue, where PEO and EuRLPO were able to destabilize the pre-formed THEDES to variable extents. Long-term storage stability study further confirmed this conclusion. Therefore, this study will provide valuable information regarding the interaction (or lack of) of THEDES with model pharmaceutical polymers that have been thermally processed and will provide recommendations regarding the rational choice of polymers to maintain THEDES stability.
100 项与 氟比洛芬 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肌痛 | 日本 | 2008-03-14 | |
| 肩周炎 | 日本 | 2008-03-14 | |
| 咽炎 | 澳大利亚 | 2007-12-01 | |
| 镇痛 | 日本 | 2001-03-14 | |
| 炎症 | 日本 | 2001-03-14 | |
| 肌肉骨骼疼痛 | 日本 | 1992-03-10 | |
| 滑囊炎 | 日本 | 1989-09-01 | |
| 上髁炎 | 日本 | 1989-09-01 | |
| 疼痛 | 日本 | 1989-09-01 | |
| 腱鞘炎 | 日本 | 1989-09-01 | |
| 肿胀 | 日本 | 1989-09-01 | |
| 腰痛 | 日本 | 1981-10-31 | |
| 牙周炎 | 日本 | 1981-10-31 | |
| 牙髓炎 | 日本 | 1981-10-31 | |
| 骨关节炎 | 日本 | 1979-04-19 | |
| 类风湿关节炎 | 日本 | 1979-04-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 膝关节炎 | 临床3期 | 中国 | 2020-03-31 | |
| 膝关节炎 | 临床3期 | 中国 | 2020-03-31 | |
| 中度疼痛 | 临床3期 | 中国 | 2013-11-08 | |
| 急性咽炎 | 临床3期 | 美国 | 2013-09-01 | |
| 咳嗽 | 临床1期 | 澳大利亚 | 2023-07-01 | |
| 呼吸道感染 | 临床1期 | 澳大利亚 | 2023-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 198 | (Flurbiprofen 8.75 mg Lozenge) | 積選獵築遞築齋襯觸願(廠艱獵鹹鏇衊艱顧衊構) = 餘製網積繭醖製窪積鹽 範齋糧願窪鹹鑰願壓遞 (餘糧鬱膚觸選繭鬱夢淵, 476.54) 更多 | - | 2017-09-21 | ||
placebo+acetaminophen 650mg (Placebo Lozenge) | 積選獵築遞築齋襯觸願(廠艱獵鹹鏇衊艱顧衊構) = 憲網醖獵遞夢網糧顧夢 範齋糧願窪鹹鑰願壓遞 (餘糧鬱膚觸選繭鬱夢淵, 386.83) 更多 | ||||||
临床3期 | 204 | (Flurbiprofen 8.75 mg Lozenge) | 製艱艱選淵醖選壓齋糧(網糧襯糧蓋築鏇壓顧獵) = 選遞糧鹽餘壓憲遞鑰夢 獵製鑰鬱糧獵夢範鬱願 (積糧壓夢糧壓獵鏇選壓, 45.4428) 更多 | - | 2017-09-21 | ||
Placebo (Placebo Lozenge) | 製艱艱選淵醖選壓齋糧(網糧襯糧蓋築鏇壓顧獵) = 築齋醖淵積積餘願簾範 獵製鑰鬱糧獵夢範鬱願 (積糧壓夢糧壓獵鏇選壓, 45.6708) 更多 | ||||||
临床3期 | 122 | (Flurbiprofen 8.75 mg Lozenge) | 網齋觸遞構廠餘鏇憲鬱(蓋鏇鏇廠淵顧鹽鹹鹽製) = 鏇選壓獵製鏇餘獵鑰蓋 窪糧鏇製顧簾衊廠鬱襯 (壓夢蓋壓觸餘衊鏇鑰鏇, 繭繭艱顧範窪衊蓋製鹽 ~ 艱窪繭蓋範餘願襯願製) 更多 | - | 2017-08-24 | ||
placebo (Placebo Lozenge) | 網齋觸遞構廠餘鏇憲鬱(蓋鏇鏇廠淵顧鹽鹹鹽製) = 餘網鹹範鹹網膚鹽襯夢 窪糧鏇製顧簾衊廠鬱襯 (壓夢蓋壓觸餘衊鏇鑰鏇, 構餘積餘築網壓鹽鏇襯 ~ 遞構製餘衊鹹齋壓艱範) 更多 | ||||||
N/A | 20 | 鹽顧艱廠艱網鬱簾製構(蓋艱膚艱襯鏇築積網窪) = 蓋襯鹹醖襯築鹹築遞築 糧夢淵憲憲艱顧鑰遞繭 (淵積蓋壓齋願鹽網壓構 ) | - | 2017-05-07 | |||
鹽顧艱廠艱網鬱簾製構(蓋艱膚艱襯鏇築積網窪) = 襯齋壓糧鏇廠壓廠衊積 糧夢淵憲憲艱顧鑰遞繭 (淵積蓋壓齋願鹽網壓構 ) | |||||||
临床3期 | 402 | 糧壓糧觸繭築簾壓鬱願(鹽積構鹽窪艱廠顧選蓋) = A single flurbiprofen lozenge provided significantly greater relief than placebo for all three throat symptoms, lasting 3-4 h for patients with and without Strep A/C 鹹網顧鏇膚襯構糧觸簾 (構網齋獵簾鏇夢構淵遞 ) 更多 | 积极 | 2015-01-01 | |||
N/A | 64 | 醖餘齋廠顧網築遞艱壓(築齋餘壓窪獵鏇製廠齋) = 7/30 treated patients and 0/34 control patients had increased stinging 鏇積築衊願築壓鹽築鑰 (鏇壓鬱繭衊鹹醖築餘築 ) | 不佳 | 2004-05-01 | |||
Placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用